Novartis India approves rights issue

What happened

In a filing with the BSE on 8 October 2026 at 07:06 PM, Novartis India (NOVARTIND) said that it has approved rights issue.

From the filing: "The Board of Directors of Evonile Pharma Limited (formally known as Novartis India Limited) has approved the raising of funds by way of Rights Issue at their Board Meeting held today i.e. ...."

Company snapshot

Novartis India is a small-cap company, with a market value of about ₹4,908 crore.

The stock last traded at ₹1,987.7, against a 52-week range of ₹672.3–₹2,588.8 (23.2% below the high).

Before this filing the shares had moved +10.3% over the month and +34.5% over three months. Average daily turnover over the last 20 sessions was about ₹44.67 crore.

Promoters held 70.68% at the end of Q2 FY27. Foreign institutions owned 0.15% and domestic institutions 1.39%.

What history shows

BCEIE has no earlier fund raising filing from this company on record since May 2026.

Market-wide, 1,525 fund raising filings with an impact score of 50 or more saw an average next-day move of +0.4%, with 48% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• How the money raised is used and, for equity instruments, the dilution for existing shareholders.

In the news

Recent coverage elsewhere (links open the original publisher):

• Novartis' listed entity renamed to Evonile Pharma Limited — Medical Dialogues, 3 Oct 2026
• Novartis returns to growth with strong Q2 2026 performance — scanx.trade, 5 Oct 2026
• Novartis India share price jumps 10% | What lies ahead for the stock? — Livemint, 5 Oct 2026
• Novartis India Share Price Today: 10% Jump, Levels, ChrysCapital — Univest, 5 Oct 2026
• Diluted earnings per share (diluted EPS) of Novartis AG Sponsored ADR – HAN:NOTA — TradingView, 29 Sept 2026

Source

• Exchange filing (PDF)